JP2013537416A5 - - Google Patents

Download PDF

Info

Publication number
JP2013537416A5
JP2013537416A5 JP2013523624A JP2013523624A JP2013537416A5 JP 2013537416 A5 JP2013537416 A5 JP 2013537416A5 JP 2013523624 A JP2013523624 A JP 2013523624A JP 2013523624 A JP2013523624 A JP 2013523624A JP 2013537416 A5 JP2013537416 A5 JP 2013537416A5
Authority
JP
Japan
Prior art keywords
region
polypeptide
polypeptide according
amino acid
igg
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2013523624A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013537416A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/EP2011/063857 external-priority patent/WO2012020096A1/en
Publication of JP2013537416A publication Critical patent/JP2013537416A/ja
Publication of JP2013537416A5 publication Critical patent/JP2013537416A5/ja
Pending legal-status Critical Current

Links

JP2013523624A 2010-08-13 2011-08-11 変異型Fc領域を含むモノマーポリペプチド及び使用方法 Pending JP2013537416A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US37342110P 2010-08-13 2010-08-13
US61/373,421 2010-08-13
PCT/EP2011/063857 WO2012020096A1 (en) 2010-08-13 2011-08-11 Monomeric polypeptides comprising variant fc regions and methods of use

Publications (2)

Publication Number Publication Date
JP2013537416A JP2013537416A (ja) 2013-10-03
JP2013537416A5 true JP2013537416A5 (cg-RX-API-DMAC7.html) 2014-09-25

Family

ID=44630039

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013523624A Pending JP2013537416A (ja) 2010-08-13 2011-08-11 変異型Fc領域を含むモノマーポリペプチド及び使用方法

Country Status (6)

Country Link
US (1) US20130177555A1 (cg-RX-API-DMAC7.html)
EP (1) EP2603526A1 (cg-RX-API-DMAC7.html)
JP (1) JP2013537416A (cg-RX-API-DMAC7.html)
AU (1) AU2011288412A1 (cg-RX-API-DMAC7.html)
CA (1) CA2808154A1 (cg-RX-API-DMAC7.html)
WO (1) WO2012020096A1 (cg-RX-API-DMAC7.html)

Families Citing this family (74)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE47770E1 (en) 2002-07-18 2019-12-17 Merus N.V. Recombinant production of mixtures of antibodies
PT1523496E (pt) 2002-07-18 2011-09-29 Merus B V Produção de misturas de anticorpos de forma recombinante
JP5620626B2 (ja) 2005-03-31 2014-11-05 中外製薬株式会社 会合制御によるポリペプチド製造方法
CA2647846C (en) 2006-03-31 2016-06-21 Chugai Seiyaku Kabushiki Kaisha Methods for controlling blood pharmacokinetics of antibodies
EP4218801A3 (en) 2006-03-31 2023-08-23 Chugai Seiyaku Kabushiki Kaisha Antibody modification method for purifying bispecific antibody
PL2202245T3 (pl) 2007-09-26 2017-02-28 Chugai Seiyaku Kabushiki Kaisha Sposób modyfikowania punktu izoelektrycznego przeciwciała poprzez podstawienie aminokwasu w cdr
WO2009041613A1 (ja) 2007-09-26 2009-04-02 Chugai Seiyaku Kabushiki Kaisha 抗体定常領域改変体
US20120071634A1 (en) 2009-03-19 2012-03-22 Chugai Seiyaku Kabushiki Kaisha Antibody Constant Region Variant
US9228017B2 (en) 2009-03-19 2016-01-05 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variant
US10435458B2 (en) 2010-03-04 2019-10-08 Chugai Seiyaku Kabushiki Kaisha Antibody constant region variants with reduced Fcgammar binding
CN103298937B (zh) 2010-11-17 2016-05-25 中外制药株式会社 具有代替凝血因子viii的功能的功能的多特异性抗原结合分子
CN109111524B (zh) 2011-10-31 2022-10-28 中外制药株式会社 控制了重链与轻链的缔合的抗原结合分子
EP2825557B1 (en) 2012-03-16 2017-06-28 The U.S.A. as represented by the Secretary, Department of Health and Human Services Soluble engineered monomeric fc
ES2740749T3 (es) 2012-04-20 2020-02-06 Merus Nv Métodos y medios para la producción de moléculas heterodiméricas similares a Ig
DK2900694T3 (en) 2012-09-27 2018-11-19 Merus Nv BISPECIFIC IGG ANTIBODIES AS T-CELL ACTIVATORS
JP6581505B2 (ja) * 2012-10-03 2019-09-25 ザイムワークス,インコーポレイテッド 重鎖および軽鎖ポリペプチドの対を定量化する方法
US9914785B2 (en) 2012-11-28 2018-03-13 Zymeworks Inc. Engineered immunoglobulin heavy chain-light chain pairs and uses thereof
KR102545617B1 (ko) 2012-11-28 2023-06-20 자임워크스 비씨 인코포레이티드 가공된 면역글로불린 중쇄-경쇄 쌍 및 이들의 용도
WO2014145159A2 (en) * 2013-03-15 2014-09-18 Permeon Biologics, Inc. Charge-engineered antibodies or compositions of penetration-enhanced targeting proteins and methods of use
CN105764922B (zh) * 2013-09-27 2020-07-17 中外制药株式会社 多肽异源多聚体的制备方法
SG10201913507SA (en) 2014-05-02 2020-02-27 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
BR112016027888A2 (pt) 2014-05-28 2017-10-24 Zymeworks Inc construto de polipeptídeo de ligação ao antígeno isolado, polinucleotídeo isolado ou um conjunto de polinucleotídeos isolados, vetor ou conjunto de vetores, célula isolada, composição farmacêutica, uso do construto, método para tratar um sujeito com uma doença ou distúrbio, método para obter um construto, método para preparar um construto, meio de armazenamento legível por computador, método para produzir um construto de polipeptídeo de ligação com antígeno bi-específico e método para preparar um construto de polipeptídeo de ligação com antígeno isolado
US9616114B1 (en) 2014-09-18 2017-04-11 David Gordon Bermudes Modified bacteria having improved pharmacokinetics and tumor colonization enhancing antitumor activity
MA40764A (fr) 2014-09-26 2017-08-01 Chugai Pharmaceutical Co Ltd Agent thérapeutique induisant une cytotoxicité
US20160130324A1 (en) 2014-10-31 2016-05-12 Shire Human Genetic Therapies, Inc. C1 Inhibitor Fusion Proteins and Uses Thereof
US10865253B2 (en) * 2014-12-19 2020-12-15 Genmab A/S Rodent bispecific heterodimeric proteins
AU2016219350A1 (en) 2015-02-10 2017-08-24 Minerva Biotechnologies Corporation Humanized anti-MUC1* antibodies
US11142587B2 (en) 2015-04-01 2021-10-12 Chugai Seiyaku Kabushiki Kaisha Method for producing polypeptide hetero-oligomer
US10676723B2 (en) 2015-05-11 2020-06-09 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN107835693B (zh) * 2015-06-12 2021-11-02 联亚药业股份有限公司 免疫球蛋白融合蛋白及其用途
JP7010811B2 (ja) 2015-07-10 2022-02-10 メルス ナムローゼ フェンノートシャップ ヒトcd3結合抗体
PL3359576T3 (pl) 2015-10-08 2025-04-14 Zymeworks Bc Inc. Konstrukty polipeptydowe wiążące antygen zawierające łańcuchy lekkie kappa i lambda oraz ich zastosowania
US11649262B2 (en) 2015-12-28 2023-05-16 Chugai Seiyaku Kabushiki Kaisha Method for promoting efficiency of purification of Fc region-containing polypeptide
ES2972740T3 (es) 2016-03-02 2024-06-14 Momenta Pharmaceuticals Inc Procedimientos relacionados con construcciones de Fc modificadas genéticamente
MX2018010988A (es) 2016-03-14 2019-01-21 Chugai Pharmaceutical Co Ltd Farmaco terapeutico que induce lesion celular para usarse en terapia de cancer.
MA45473A (fr) 2016-04-04 2019-02-13 Shire Human Genetic Therapies Inhibiteur de c1 estérase conjugué et ses utilisations
MX2018012648A (es) 2016-04-28 2019-01-30 Chugai Pharmaceutical Co Ltd Preparaciones que contienen anticuerpos.
NZ749292A (en) 2016-05-23 2025-08-29 Momenta Pharmaceuticals Inc Compositions and methods related to engineered fc constructs
CN109475627B (zh) 2016-05-26 2023-01-06 齐鲁普吉湾生物治疗公司 抗体混合物
CN119120423A (zh) 2016-07-01 2024-12-13 分解治疗有限责任公司 优化的二核酸酶融合体和方法
CN109476763B (zh) * 2016-07-19 2023-11-07 伊班绰斯有限责任公司 双特异性蛋白质及其制备方法
US11180535B1 (en) 2016-12-07 2021-11-23 David Gordon Bermudes Saccharide binding, tumor penetration, and cytotoxic antitumor chimeric peptides from therapeutic bacteria
US11129906B1 (en) 2016-12-07 2021-09-28 David Gordon Bermudes Chimeric protein toxins for expression by therapeutic bacteria
CN110650748B (zh) 2017-01-06 2024-01-02 动量制药公司 与经工程改造的Fc构建体相关的组合物和方法
EP3573640A4 (en) * 2017-01-30 2021-04-28 The Ohio State Innovation Foundation PASSIVE ANTIBODY DEPENDENT CELLULAR MEDIATION ACTIVATION
WO2018144784A1 (en) * 2017-02-01 2018-08-09 Smet Pharmaceutical Inc. MONOMERIC HUMAN IgG1 Fc AND BISPECIFIC ANTIBODIES
CA3221995C (en) 2017-02-08 2024-05-28 Dragonfly Therapeutics, Inc. Multi-specific binding proteins for activation of natural killer cells and therapeutic uses thereof to treat cancer
SG11201907646YA (en) 2017-02-20 2019-09-27 Dragonfly Therapeutics Inc Proteins binding her2, nkg2d and cd16
US12054544B2 (en) 2017-02-24 2024-08-06 Chugai Seiyaku Kabushiki Kaisha Compositions comprising antigen-binding molecules
MX2019014000A (es) * 2017-05-23 2020-07-29 Dragonfly Therapeutics Inc Una proteína que se une a nkg2d, cd16 y un antígeno asociado a un tumor.
WO2019035010A1 (en) 2017-08-15 2019-02-21 Kindred Biosciences, Inc. IGG VARIANTS FOR VETERINARY USE
EP3672986A1 (en) 2017-08-22 2020-07-01 Sanabio, LLC Soluble interferon receptors and uses thereof
CN109705211B (zh) * 2017-10-26 2020-08-18 苏州复融生物技术有限公司 一种IgG1 Fc单体及其应用
SG11202003833TA (en) 2017-11-01 2020-05-28 Chugai Pharmaceutical Co Ltd Antibody variant and isoform with lowered biological activity
KR20200118824A (ko) 2018-02-08 2020-10-16 드래곤플라이 쎄라퓨틱스, 인크. 자연 살해 세포를 활성화시키는 다중-특이성 결합 단백질을 수반하는 암의 병용 요법
PT3749346T (pt) 2018-02-08 2024-09-05 Dragonfly Therapeutics Inc Combinações de domínios variáveis de anticorpos dirigidas ao receptor nkg2d
CA3091424A1 (en) 2018-02-20 2019-08-29 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind cd33, nkg2d, and cd16, and methods of use
WO2019201892A1 (en) 2018-04-17 2019-10-24 Universität Heidelberg Means and methods for the treatment of angiogenesis-, fibrosis- and cancer-related diseases with protein oligomers comprising nc-1-fc
EA202091888A1 (ru) 2018-08-08 2020-10-23 Драгонфлай Терапьютикс, Инк. Вариабельные домены антител, нацеленные на рецептор nkg2d
CA3108646A1 (en) 2018-08-08 2020-02-13 Dragonfly Therapeutics, Inc. Proteins binding nkg2d, cd16 and a tumor-associated antigen
AU2019318083A1 (en) 2018-08-08 2021-02-25 Dragonfly Therapeutics, Inc. Multi-specific binding proteins that bind BCMA, NKG2D and CD16, and methods of use
JP7523349B2 (ja) * 2018-08-29 2024-07-26 中外製薬株式会社 抗体半分子、および抗体半分子のホモ二量体形成を抑制する方法
TWI874341B (zh) 2018-12-18 2025-03-01 美商健生生物科技公司 產生異二聚體抗體之方法
US20220064263A1 (en) * 2018-12-27 2022-03-03 Kindred Biosciences, Inc. IGG FC Variants for Veterinary Use
MX2022013944A (es) 2020-05-06 2022-11-30 Dragonfly Therapeutics Inc Proteinas que se unen al receptor activador de celulas asesinas naturales grupo 2 miembro d (nkg2d), cumulo de diferenciacion (cd16) y miembro a de la familia de dominios de lectina tipo c 12 (clec12a).
CN116829193A (zh) 2020-11-03 2023-09-29 昂科纳诺医药公司 治疗性pH响应性组合物
EP4259194A4 (en) * 2020-12-10 2025-03-19 Invenra Inc. Orthogonal mutations for heterodimerization
CN113321736B (zh) * 2020-12-30 2024-01-09 苏州复融生物技术有限公司 一种长效化白介素15融合蛋白及其制备方法和应用
CN117440969A (zh) * 2021-01-11 2024-01-23 阿迪马布有限责任公司 被工程化为优先进行ch3异源二聚化的变体ch3结构域、包括所述变体ch3结构域的多特异性抗体和其制备方法
JP2024508894A (ja) 2021-03-03 2024-02-28 ドラゴンフライ セラピューティクス, インコーポレイテッド Nkg2d、cd16、及び腫瘍関連抗原に結合する多特異性結合タンパク質を使用して癌を治療する方法
CN113261566B (zh) * 2021-04-14 2022-03-11 湖南工业大学 一种碱式次氯酸镁负载金属有机框架抑菌剂的制备方法
EP4393940A4 (en) * 2021-08-24 2025-10-15 Sunshine Lake Pharma Co Ltd GDF15 FUSION PROTEIN AND ITS USE
WO2025108310A1 (zh) * 2023-11-20 2025-05-30 江苏恒瑞医药股份有限公司 通过重组反应制备异源多聚体的方法
WO2025166165A1 (en) * 2024-02-01 2025-08-07 Zoetis Services, Llc Compositions and methods for modifying antibody effector functions

Family Cites Families (117)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4179337A (en) 1973-07-20 1979-12-18 Davis Frank F Non-immunogenic polypeptides
JPS6023084B2 (ja) 1979-07-11 1985-06-05 味の素株式会社 代用血液
US4640835A (en) 1981-10-30 1987-02-03 Nippon Chemiphar Company, Ltd. Plasminogen activator derivatives
US4671958A (en) 1982-03-09 1987-06-09 Cytogen Corporation Antibody conjugates for the delivery of compounds to target sites
US4496689A (en) 1983-12-27 1985-01-29 Miles Laboratories, Inc. Covalently attached complex of alpha-1-proteinase inhibitor with a water soluble polymer
US4625014A (en) 1984-07-10 1986-11-25 Dana-Farber Cancer Institute, Inc. Cell-delivery agent
US4542225A (en) 1984-08-29 1985-09-17 Dana-Farber Cancer Institute, Inc. Acid-cleavable compound
DE3675588D1 (de) 1985-06-19 1990-12-20 Ajinomoto Kk Haemoglobin, das an ein poly(alkenylenoxid) gebunden ist.
US6548640B1 (en) 1986-03-27 2003-04-15 Btg International Limited Altered antibodies
US4791192A (en) 1986-06-26 1988-12-13 Takeda Chemical Industries, Ltd. Chemically modified protein with polyethyleneglycol
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5567610A (en) 1986-09-04 1996-10-22 Bioinvent International Ab Method of producing human monoclonal antibodies and kit therefor
AU600575B2 (en) 1987-03-18 1990-08-16 Sb2, Inc. Altered antibodies
US5258498A (en) 1987-05-21 1993-11-02 Creative Biomolecules, Inc. Polypeptide linkers for production of biosynthetic proteins
US5677425A (en) 1987-09-04 1997-10-14 Celltech Therapeutics Limited Recombinant antibody
US5141648A (en) 1987-12-02 1992-08-25 Neorx Corporation Methods for isolating compounds using cleavable linker bound matrices
GB8823869D0 (en) 1988-10-12 1988-11-16 Medical Res Council Production of antibodies
FI903489A0 (fi) 1988-11-11 1990-07-10 Medical Res Council Ligander med en enda sektion, receptorer innehaollande naemnda ligander, foerfaranden foer deras framstaellning samt anvaendning av liganderna och receptorerna.
US5175384A (en) 1988-12-05 1992-12-29 Genpharm International Transgenic mice depleted in mature t-cells and methods for making transgenic mice
US6291161B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertiore
US6291158B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for tapping the immunological repertoire
US6680192B1 (en) 1989-05-16 2004-01-20 Scripps Research Institute Method for producing polymers having a preselected activity
US6291160B1 (en) 1989-05-16 2001-09-18 Scripps Research Institute Method for producing polymers having a preselected activity
DE69133566T2 (de) 1990-01-12 2007-12-06 Amgen Fremont Inc. Bildung von xenogenen Antikörpern
US6075181A (en) 1990-01-12 2000-06-13 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6673986B1 (en) 1990-01-12 2004-01-06 Abgenix, Inc. Generation of xenogeneic antibodies
US20040010810A1 (en) 1990-01-12 2004-01-15 Abgenix, Inc. Generation of xenogeneic antibodies
US6713610B1 (en) 1990-01-12 2004-03-30 Raju Kucherlapati Human antibodies derived from immunized xenomice
US6657103B1 (en) 1990-01-12 2003-12-02 Abgenix, Inc. Human antibodies derived from immunized xenomice
US6150584A (en) 1990-01-12 2000-11-21 Abgenix, Inc. Human antibodies derived from immunized xenomice
US5229275A (en) 1990-04-26 1993-07-20 Akzo N.V. In-vitro method for producing antigen-specific human monoclonal antibodies
US6916605B1 (en) 1990-07-10 2005-07-12 Medical Research Council Methods for producing members of specific binding pairs
US6172197B1 (en) 1991-07-10 2001-01-09 Medical Research Council Methods for producing members of specific binding pairs
GB9015198D0 (en) 1990-07-10 1990-08-29 Brien Caroline J O Binding substance
US5545806A (en) 1990-08-29 1996-08-13 Genpharm International, Inc. Ransgenic non-human animals for producing heterologous antibodies
US5789650A (en) 1990-08-29 1998-08-04 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
US5814318A (en) 1990-08-29 1998-09-29 Genpharm International Inc. Transgenic non-human animals for producing heterologous antibodies
US5770429A (en) 1990-08-29 1998-06-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5625126A (en) 1990-08-29 1997-04-29 Genpharm International, Inc. Transgenic non-human animals for producing heterologous antibodies
WO1992003918A1 (en) 1990-08-29 1992-03-19 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
EP0546091B1 (en) 1990-08-29 2007-01-24 Pharming Intellectual Property BV Homologous recombination in mammalian cells
US5633425A (en) 1990-08-29 1997-05-27 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US6255458B1 (en) 1990-08-29 2001-07-03 Genpharm International High affinity human antibodies and human antibodies against digoxin
US5877397A (en) 1990-08-29 1999-03-02 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US5874299A (en) 1990-08-29 1999-02-23 Genpharm International, Inc. Transgenic non-human animals capable of producing heterologous antibodies
US5661016A (en) 1990-08-29 1997-08-26 Genpharm International Inc. Transgenic non-human animals capable of producing heterologous antibodies of various isotypes
US6797492B2 (en) 1991-05-17 2004-09-28 Merck & Co., Inc. Method for reducing the immunogenicity of antibody variable domains
CA2110799A1 (en) 1991-06-14 1992-12-23 Arnold H. Horwitz Microbially-produced antibody fragments and their conjugates
IE922437A1 (en) 1991-07-25 1993-01-27 Idec Pharma Corp Recombinant antibodies for human therapy
WO1993004169A1 (en) 1991-08-20 1993-03-04 Genpharm International, Inc. Gene targeting in animal cells using isogenic dna constructs
US5565332A (en) 1991-09-23 1996-10-15 Medical Research Council Production of chimeric antibodies - a combinatorial approach
DE69233745D1 (de) 1991-12-02 2008-10-23 Cambridge Antibody Tech Herstellung von Autoantikörpern auf Phagenoberflächen ausgehend von Antikörpersegmentbibliotheken
US5573905A (en) 1992-03-30 1996-11-12 The Scripps Research Institute Encoded combinatorial chemical libraries
WO1993022332A2 (en) 1992-04-24 1993-11-11 Board Of Regents, The University Of Texas System Recombinant production of immunoglobulin-like domains in prokaryotic cells
US5639641A (en) 1992-09-09 1997-06-17 Immunogen Inc. Resurfacing of rodent antibodies
US5981175A (en) 1993-01-07 1999-11-09 Genpharm Internation, Inc. Methods for producing recombinant mammalian cells harboring a yeast artificial chromosome
US5885573A (en) 1993-06-01 1999-03-23 Arch Development Corporation Methods and materials for modulation of the immunosuppressive activity and toxicity of monoclonal antibodies
CA2163345A1 (en) 1993-06-16 1994-12-22 Susan Adrienne Morgan Antibodies
US6180377B1 (en) 1993-06-16 2001-01-30 Celltech Therapeutics Limited Humanized antibodies
US5625825A (en) 1993-10-21 1997-04-29 Lsi Logic Corporation Random number generating apparatus for an interface unit of a carrier sense with multiple access and collision detect (CSMA/CD) ethernet data network
US5643763A (en) 1994-11-04 1997-07-01 Genpharm International, Inc. Method for making recombinant yeast artificial chromosomes by minimizing diploid doubling during mating
US5641870A (en) 1995-04-20 1997-06-24 Genentech, Inc. Low pH hydrophobic interaction chromatography for antibody purification
US5869046A (en) 1995-04-14 1999-02-09 Genentech, Inc. Altered polypeptides with increased half-life
US6121022A (en) 1995-04-14 2000-09-19 Genentech, Inc. Altered polypeptides with increased half-life
US6632976B1 (en) 1995-08-29 2003-10-14 Kirin Beer Kabushiki Kaisha Chimeric mice that are produced by microcell mediated chromosome transfer and that retain a human antibody gene
DE19544393A1 (de) 1995-11-15 1997-05-22 Hoechst Schering Agrevo Gmbh Synergistische herbizide Mischungen
US6277375B1 (en) 1997-03-03 2001-08-21 Board Of Regents, The University Of Texas System Immunoglobulin-like domains with increased half-lives
GB9722131D0 (en) 1997-10-20 1997-12-17 Medical Res Council Method
US6528624B1 (en) 1998-04-02 2003-03-04 Genentech, Inc. Polypeptide variants
US6194551B1 (en) 1998-04-02 2001-02-27 Genentech, Inc. Polypeptide variants
GB9809951D0 (en) 1998-05-08 1998-07-08 Univ Cambridge Tech Binding molecules
PL209786B1 (pl) 1999-01-15 2011-10-31 Genentech Inc Przeciwciało zawierające wariant regionu Fc ludzkiej IgG1, przeciwciało wiążące czynnik wzrostu śródbłonka naczyń oraz immunoadhezyna
US7183387B1 (en) 1999-01-15 2007-02-27 Genentech, Inc. Polypeptide variants with altered effector function
US6737056B1 (en) 1999-01-15 2004-05-18 Genentech, Inc. Polypeptide variants with altered effector function
US6833268B1 (en) 1999-06-10 2004-12-21 Abgenix, Inc. Transgenic animals for producing specific isotypes of human antibodies via non-cognate switch regions
HUP0204475A2 (en) 2000-02-11 2003-04-28 Merck Patent Gmbh Enhancing the circulating half-life of antibody-based fusion proteins
US6291591B1 (en) 2000-04-13 2001-09-18 Bridgestone Corporation Process for producing blends of syndiotactic 1,2-polybutadiene and rubbery elastomers with a chromium-based catalyst system
EP1522590B1 (en) 2000-06-28 2009-08-26 Glycofi, Inc. Methods for producing modified glycoproteins
EP1355919B1 (en) 2000-12-12 2010-11-24 MedImmune, LLC Molecules with extended half-lives, compositions and uses thereof
CA2447851C (en) 2001-06-28 2012-08-28 Domantis Limited Dual-specific ligand and its use
US20050069962A1 (en) 2001-10-12 2005-03-31 Archer Robert M Antibody complexes and methods for immunolabeling
US20040002587A1 (en) 2002-02-20 2004-01-01 Watkins Jeffry D. Fc region variants
US8188231B2 (en) 2002-09-27 2012-05-29 Xencor, Inc. Optimized FC variants
US7317091B2 (en) 2002-03-01 2008-01-08 Xencor, Inc. Optimized Fc variants
WO2003086443A1 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
AU2003234090A1 (en) 2002-04-11 2003-10-27 Medimmune Vaccines, Inc. Spray freeze dry of compositions for pulmonary administration
AU2003221888B2 (en) 2002-04-11 2008-11-06 Medimmune, Llc Preservation of bioactive materials by spray drying
AU2003247337B2 (en) 2002-04-11 2007-09-06 Medimmune, Llc Preservation of bioactive materials by freeze dried foam
DK1517921T3 (da) 2002-06-28 2006-10-09 Domantis Ltd Immunglobulin-enkeltvariable antigen-bindende domæner og dobbeltspecifikke konstruktioner deraf
US20060235208A1 (en) 2002-09-27 2006-10-19 Xencor, Inc. Fc variants with optimized properties
US7217797B2 (en) 2002-10-15 2007-05-15 Pdl Biopharma, Inc. Alteration of FcRn binding affinities or serum half-lives of antibodies by mutagenesis
WO2004058156A2 (en) 2002-12-17 2004-07-15 Medimmune Vaccines, Inc. High pressure spray-dry of bioactive materials
AU2003290330A1 (en) 2002-12-27 2004-07-22 Domantis Limited Dual specific single domain antibodies specific for a ligand and for the receptor of the ligand
ES2897506T3 (es) 2003-01-09 2022-03-01 Macrogenics Inc Identificación y modificación de anticuerpos con regiones Fc variantes y métodos de utilización de los mismos
EP1599504B1 (en) 2003-02-25 2014-12-03 Vaccibody AS Modified antibody
AU2004220325B2 (en) 2003-06-30 2011-05-12 Domantis Limited Polypeptides
GB0324368D0 (en) 2003-10-17 2003-11-19 Univ Cambridge Tech Polypeptides including modified constant regions
PL1706424T3 (pl) 2004-01-12 2010-04-30 Mentrik Biotech Llc Warianty regionu Fc
US7276585B2 (en) 2004-03-24 2007-10-02 Xencor, Inc. Immunoglobulin variants outside the Fc region
AU2005274905B2 (en) 2004-08-04 2010-12-23 Mentrik Biotech, Llc Variant Fc regions
WO2006031994A2 (en) * 2004-09-14 2006-03-23 Xencor, Inc. Monomeric immunoglobulin fc domains
CA2587617C (en) 2004-11-12 2011-02-01 Xencor, Inc. Fc variants with altered binding to fcrn
US8802820B2 (en) 2004-11-12 2014-08-12 Xencor, Inc. Fc variants with altered binding to FcRn
US20070135620A1 (en) 2004-11-12 2007-06-14 Xencor, Inc. Fc variants with altered binding to FcRn
CN101506238B (zh) 2005-06-30 2013-11-06 森托科尔公司 具有提高治疗活性的方法和成分
WO2007005612A2 (en) * 2005-07-01 2007-01-11 Medimmune, Inc. An integrated approach for generating multidomain protein therapeutics
WO2007055916A2 (en) 2005-11-07 2007-05-18 The Rockefeller University Reagents, methods and systems for selecting a cytotoxic antibody or variant thereof
EA016609B1 (ru) 2005-11-28 2012-06-29 Генмаб А/С Рекомбинантные моновалентные антитела и способы их получения
WO2007084926A2 (en) 2006-01-17 2007-07-26 Biolex Therapeutics, Inc. Compositions and methods for humanization and optimization of n-glycans in plants
EP2087111A2 (en) * 2007-03-19 2009-08-12 Medimmune Limited Polypeptide variants
EP1995309A1 (en) 2007-05-21 2008-11-26 Vivalis Recombinant protein production in avian EBx® cells
EP3153524B1 (en) * 2008-12-03 2025-04-23 Genmab A/S Antibody variants having modifications in the constant region
ES2688978T3 (es) * 2009-11-23 2018-11-07 Amgen Inc. Anticuerpo monomérico Fc
GB2476671B (en) 2010-01-04 2014-11-26 Plastic Logic Ltd Touch-sensing systems
JP5240316B2 (ja) 2010-10-26 2013-07-17 株式会社デンソー 車両乗員非操作運転システム
ES2758994T3 (es) * 2010-11-05 2020-05-07 Zymeworks Inc Diseño anticuerpo heterodimérico estable con mutaciones en el dominio Fc
CN103459572A (zh) 2011-04-05 2013-12-18 雪佛龙奥伦耐有限责任公司 低粘度船用气缸润滑油组合物

Similar Documents

Publication Publication Date Title
JP2013537416A5 (cg-RX-API-DMAC7.html)
TWI868050B (zh) 用於改良儲存及投與之包含雙特異性抗體構築體之醫藥組成物
CA2896888C (en) Anti-tnf-anti-il-17 bispecific antibodies
DK2536764T3 (en) ANTI-CD28 HUMANIZED ANTIBODIES
JP2014519830A5 (cg-RX-API-DMAC7.html)
TWI671315B (zh) 具有交叉結合區定向之雙重可變區類抗體結合蛋白
JP6647208B2 (ja) 抗il−17抗体、その生産および使用のための方法
JP7261307B2 (ja) 新規二重特異性cd3/cd20ポリペプチド複合体
JP2020018301A (ja) FcRnに特異的な抗体
US20230250133A1 (en) Methods of purifying a product
RU2018107427A (ru) Однодоменное антитело и его производные белки к лиганду-1 белка программируемой смерти клеток(pdli)
JP2018510617A5 (cg-RX-API-DMAC7.html)
JP7292526B2 (ja) 操作された抗il-2抗体
JP7097293B2 (ja) ヒトFc受容体に結合する融合タンパク質
PH12014502333B1 (en) Anti-baff-anti-il-17 bispecific antibodies
JP2014530001A5 (cg-RX-API-DMAC7.html)
CN116323671A (zh) 具有增加的选择性的多靶向性双特异性抗原结合分子
HRP20240102T1 (hr) Monoklonsko protutijelo koje antagonizira i inhibira vezanje između humanog pd-1 antigena i njegovog liganda, postupak njegove priprave i primjena
AU2021274522B2 (en) Methods and means for the production of Ig-like molecules
WO2022166728A1 (zh) 双特异性抗体
RU2019123112A (ru) Анти-il-5 антитела
HRP20161096T1 (hr) Antigenski vežući proteini specifični za komponentu p serumskog amiloida
CN114829385A (zh) 包含il-7变体的双功能分子
TW202027788A (zh) 雙特異性抗體構建體之下游加工
JP2019518473A5 (cg-RX-API-DMAC7.html)